Online inquiry

IVTScrip™ mRNA-Anti-IFNAR1&IFNAR2, PEG-IFN-SA(Cap 1, Pseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ13045MR)

This product GTTS-WQ13045MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 1 & Pseudo-UTP. It ecodes the monoclonal antibody that targets IFNAR1&IFNAR2 gene. The antibody can be applied in Hepatitis C research.
Specifications
Product type mRNA
Modified bases Pseudo-UTP
5' Cap Cap 1
Species Homo sapiens
RefSeq NM_000629.3; NM_000874.5
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 3454; 3455
UniProt ID P17181; P48551
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-IFNAR1&IFNAR2, PEG-IFN-SA(Cap 1, Pseudo-UTP, 30 nt-poly(A)) (GTTS-WQ13045MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ11144MR IVTScrip™ mRNA-Anti-IFNA1, MDX-1103(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA MDX-1103
GTTS-WQ4951MR IVTScrip™ mRNA-Anti-GP, c13C6-FR1-N(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA c13C6-FR1-N
GTTS-WQ6414MR IVTScrip™ mRNA-Anti-PDCD1, CT-011(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA CT-011
GTTS-WQ6845MR IVTScrip™ mRNA-Anti-IL3RA, DT-IL-3(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA DT-IL-3
GTTS-WQ485MR IVTScrip™ mRNA-Anti-SELP, 42-89-glycoprotein(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA 42-89-glycoprotein
GTTS-WQ10292MR IVTScrip™ mRNA-Anti-PCSK9, LGT209(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA LGT209
GTTS-WQ3135MR IVTScrip™ mRNA-Anti-C3&C4, APT070(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA APT070
GTTS-WQ11304MR IVTScrip™ mRNA-Anti-ITGAV&ITGB3, MEDI-522(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA MEDI-522
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW